Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,971 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,884 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05804916 | Optical Surface Monitoring Technology-Guided Large-Segment Radiotherapy for Breast Cancer | recruiting | Phase 2 / Phase 3 | 556 | Peking Union Medical College HospitalOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT05805098 | Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML(VHA) | recruiting | Phase 2 / Phase 3 | 60 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 7, 2023 |
| clinicaltrials |
| NCT05231135 | A Registry Study on HIV-related Lymphoma | recruiting | — | 300 | Rotkreuzklinikum München gGmbHOTHER | 4 | Apr 6, 2023 | clinicaltrials |
| NCT04047953 | Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma | recruiting | N/A | 95 | Peking University Cancer Hospital & InstituteOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT05799898 | Fast-Track Cardiovascular Assessment for Suspicion of Cardiovascular Events on Immunecheckpoint Inhibitors(FAST-TRACK) | recruiting | — | 200 | Institut Mutualiste MontsourisOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT05800054 | Effect of NST Whole-course Nutritional Management on Nutritional Status and Adverse Reactions in Esophageal Cancer | recruiting | N/A | 210 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT05800340 | Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC | recruiting | Phase 2 | 30 | Guangdong Provincial People's HospitalOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT05797077 | Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA | recruiting | Phase 3 | 346 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT05797493 | Panomic Approach to Immune-Connected Assays in Small Cell Lung Cancer(PICASSO) | recruiting | — | 100 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT05204862 | Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 240 | TiumBio Co., Ltd.INDUSTRY | 2 | Apr 3, 2023 | clinicaltrials |
| NCT05539833 | KSH01-TCRT Solid Tumors(KSH01-TCRT) | recruiting | Early Phase 1 | 50 | TCRx Therapeutics Co.LtdINDUSTRY | 1 | Apr 3, 2023 | clinicaltrials |
| NCT05580796 | KSH01-R02-101 Solid Tumors | recruiting | Early Phase 1 | 50 | TCRx Therapeutics Co.LtdINDUSTRY | 1 | Apr 3, 2023 | clinicaltrials |
| NCT05627180 | Tailored Health Literacy Follow-up in Cancer | recruiting | N/A | 150 | Lovisenberg Diakonale HospitalOTHER | 1 | Apr 3, 2023 | clinicaltrials |
| NCT03385720 | Submandibular Gland Preservation in Neck Dissection | recruiting | N/A | 200 | Guang-Yan YuOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT05243082 | Endoscopic Ultrasound Guided Radio Frequency Ablation of Pancreatic Neuroendocrine Neoplasms(ERFA-PNET) | recruiting | N/A | 20 | Oslo University HospitalOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT04621201 | Genomic Profiles Analysis in Children, Adolescents and Young Adult With Sarcomas | recruiting | — | 120 | Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'AnnaOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05034991 | The Role of Endometrial Blood Flow in Endometrial Cancer | recruiting | — | 75 | Far Eastern Memorial HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05054296 | Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring | recruiting | Phase 2 | 200 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05718128 | Clinical Study of Endocardial Myocardial Biopsy | recruiting | Phase 4 | 100 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 28, 2023 | clinicaltrials |
| NCT05255471 | MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.(MITO 35B) | recruiting | Phase 3 | 200 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05521802 | A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 92 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Mar 24, 2023 | clinicaltrials |
| NCT01763125 | Establishment of a Tumor Bank for Blood Samples | recruiting | — | 10,000 | Medical University of ViennaOTHER | 4 | Mar 23, 2023 | clinicaltrials |
| NCT01789229 | Establishment of a Tumor Bank for Tissue Samples | recruiting | — | 10,000 | Medical University of ViennaOTHER | 3 | Mar 23, 2023 | clinicaltrials |
| NCT05740995 | Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma | recruiting | — | 40 | Shanghai Zhongshan HospitalOTHER | 1 | Mar 21, 2023 | clinicaltrials |
| NCT05778253 | The Role of ctDNA Testing Plus AI-based Pathology in Resectable LSCC | recruiting | — | 50 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | Mar 21, 2023 | clinicaltrials |
| NCT05638594 | Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer | recruiting | Phase 2 | 236 | Shengjing HospitalOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT05775419 | Comparison of Chemoradiotherapy and Chemoradiotherapy Combined With Consolidation Chemotherapy for ESCC | recruiting | N/A | 1,216 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT05286957 | MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC(Seagull) | recruiting | Phase 2 | 60 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Mar 17, 2023 | clinicaltrials |
| NCT05732051 | Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients(NARNIA) | recruiting | Phase 2 | 60 | University Hospital, AkershusOTHER | 1 | Mar 17, 2023 | clinicaltrials |
| NCT05772923 | Organ Preservation in Rectal Cancer: Contact X-ray Brachytherapy vs Extending the Waiting Interval and Local Excision(OPAXX) | recruiting | N/A | 168 | The Netherlands Cancer InstituteOTHER | 1 | Mar 17, 2023 | clinicaltrials |
| NCT00574327 | Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry | recruiting | — | 3,000 | Midwest Biomedical ResearchOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT05766410 | A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC(ORACLE-RIPA) | recruiting | Phase 2 | 60 | National Taiwan University HospitalOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT05772208 | Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy | recruiting | Phase 3 | 459 | Fudan UniversityOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT05595603 | Zoledronic Acid-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Bone Tumor After Intralesional Curettage | recruiting | Phase 2 | 153 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 15, 2023 | clinicaltrials |
| NCT05736965 | A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia(SAV) | recruiting | Phase 2 | 58 | Shanghai Tong Ren HospitalOTHER | 1 | Mar 15, 2023 | clinicaltrials |
| NCT05736978 | Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results(AVS) | recruiting | Phase 2 | 58 | Shanghai Tong Ren HospitalOTHER | 1 | Mar 15, 2023 | clinicaltrials |
| NCT05768490 | Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases | recruiting | Phase 3 | 232 | Sun Yat-sen UniversityOTHER | 1 | Mar 14, 2023 | clinicaltrials |
| NCT05768503 | Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC | recruiting | Phase 3 | 176 | Sun Yat-sen UniversityOTHER | 1 | Mar 14, 2023 | clinicaltrials |
| NCT04483804 | Application of Radiomics in Breast Cancer | recruiting | — | 2,000 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT05733000 | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors | recruiting | Phase 2 | 94 | Northwestern UniversityOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT05762900 | Ultra-hypofractioNated Adjuvant Radiotherapy ± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients(UNIQUE) | recruiting | Phase 2 | 65 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT05536102 | The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy) | recruiting | Phase 2 | 38 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Mar 9, 2023 | clinicaltrials |
| NCT05648019 | CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol | recruiting | Phase 2 | 40 | KK Women's and Children's HospitalOTHER_GOV | 1 | Mar 9, 2023 | clinicaltrials |
| NCT05761054 | Sarcoma Preoperative Radiation With Simultaneous INTegrated Boost (SPRINT)(SPRINT) | recruiting | N/A | 33 | Azienda Ospedaliero-Universitaria CareggiOTHER | 1 | Mar 9, 2023 | clinicaltrials |
| NCT04245683 | Feasibility of Non-Operative Management of Rectal Cancer in a Rural Population | recruiting | — | 50 | Bassett HealthcareOTHER | 1 | Mar 7, 2023 | clinicaltrials |
| NCT05757336 | Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer | recruiting | Phase 2 | 50 | Lu Wang, MD, PhDOTHER | 1 | Mar 7, 2023 | clinicaltrials |
| NCT04842006 | Systemic Neoadjuvant and Adjuvant Control by Precision Medicine in Rectal Cancer(SYNCOPE) | recruiting | N/A | 93 | Helsinki University Central HospitalOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT04959903 | Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT | recruiting | Phase 1 / Phase 2 | 36 | Smart Immune SASINDUSTRY | 1 | Mar 6, 2023 | clinicaltrials |
| NCT05753566 | Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer | recruiting | Phase 2 | 96 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT03183115 | RFA to Prevent Metachronous Squamous Neoplasia Recurrence After Complete Endoscopic Submucosal Dissection | recruiting | N/A | 100 | E-DA HospitalOTHER | 1 | Mar 3, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Apr 7, 2023source: clinicaltrials